August 20, 2015

Verseon Corporation (“Verseon” or the “Company”)

Verseon Acquires Research and Development Facility

Moves forward with Plans to Expand Drug Discovery Operations

FREMONT, Calif. – Verseon Corporation (AIM:VSN, VSN:London), a technology-based pharmaceutical company, has purchased a property in Fremont, California, under its wholly owned subsidiary, VRH1 LLC. The property, purchased for $8.7M, includes a building with approximately 85,000 square feet of usable space.

The acquisition of the property allows the Company to implement the planned expansion of its computing and laboratory infrastructure and staff, while benefiting from consolidation of multiple core operations. The facility will house Verseon’s state-of-the-art drug-discovery and development operations and corporate offices.

"Verseon’s current drug programs continue to make steady progress along their development paths,” said Adityo Prakash, CEO. “The new facility is integral to the Company’s growth plans, as it supports the infrastructure necessary to expand our pipeline and accelerate the progress of our existing drug programs."

For further information please contact:

Verseon Corporation +1 (510) 225 9000
Adityo Prakash, Chief Executive Officer  
Cenkos Securities (NOMAD and Broker) +44 (0) 20 7397 8900
Mark Connelly / Christopher Golden  
FTI Consulting (PR Advisers) +44 (0) 20 3727 1000
Simon Conway / Robert Winder / Matthew Moss  

About Verseon

Verseon is a pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

For more information, please visit:

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods


Drug Programs

Multiple therapeutic areas, all with unmet (or poorly met) medical needs